Paul Manning
Paul Manning is a prominent investor in AveXis, the biotech company responsible for developing Zolgensma, the world’s most expensive drug. His significant financial backing and involvement in the startup have raised questions about the motivations behind high drug prices and the commercialization of gene therapies.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| New Zealand | 1 | 6.00 | 0.04% | +0% | 4,822,233 | 2,101 | $210,000 | 92$ |
| Totals | 1 | 4,822,233 | 2,101 | $210,000 | 92$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
New Zealand:
Liquidator Paul Manning told the Bay of Plenty Times the investigation into a potential claim against a previous funder related to a government funder.
6
United States:
Paul Manning was a major investor in AveXis and made significant profits from the company's acquisition by Novartis.
5